CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $234,087 | +23308.7% | 15,700 | +27935.7% | 0.00% | – |
| Q3 2018 | $1,000 | -97.1% | 56 | -97.9% | 0.00% | – |
| Q2 2018 | $35,000 | +105.9% | 2,638 | +100.8% | 0.00% | – |
| Q1 2018 | $17,000 | +21.4% | 1,314 | -12.4% | 0.00% | – |
| Q4 2017 | $14,000 | +16.7% | 1,500 | 0.0% | 0.00% | – |
| Q3 2017 | $12,000 | +300.0% | 1,500 | -15.0% | 0.00% | – |
| Q4 2016 | $3,000 | 0.0% | 1,764 | 0.0% | 0.00% | – |
| Q3 2016 | $3,000 | -76.9% | 1,764 | -76.1% | 0.00% | – |
| Q2 2016 | $13,000 | -61.8% | 7,374 | -70.8% | 0.00% | – |
| Q1 2016 | $34,000 | -20.9% | 25,274 | 0.0% | 0.00% | – |
| Q4 2015 | $43,000 | -4.4% | 25,274 | +8.0% | 0.00% | – |
| Q3 2015 | $45,000 | -28.6% | 23,400 | 0.0% | 0.00% | – |
| Q2 2015 | $63,000 | – | 23,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |